June 16th 2025
Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with high-risk neuroblastoma.
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
Novel Therapies Set to Revolutionize Glioma Treatment
February 9th 2016Targeted Oncology spoke with Andrew S. Chi, MD, PhD, head of Neuro-Oncology at NYU Langone's Laura and Isaac Perlmutter Cancer Center, on recent developments in the treatment paradigm for patients with brain cancer, including his recent study into mutant IDH1 gliomas and the role of the NAD metabolite.
Read More
Dr. Nicholas A. Butowski on Convection-Enhanced Delivery of Nanoliposomal Irinotecan in Brain Cancer
February 9th 2016Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Watch
Dr. Rimas Lukas on Searching for Biomarkers in Glioblastoma
February 9th 2016​Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, discusses the next steps following a phase I study looking at atezolizumab in glioblastoma.
Watch
Dr. Amy Heimberger on Better Imaging and Combination Therapies in Glioblastoma
January 30th 2016Heimberger says the treatment paradigm's future is two-pronged, in that it will consist of both combination therapies that activate the immune system and prevent immunosuppression, as well as understand CT and MRI scans of brain cancer patients.
Watch
Dr. David Reardon on Targeting Brain Tumors and Monitoring Resistances
January 29th 2016David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment.
Watch
Dr. Susan Panullo on Optune Versus Salvage Chemotherapy in Glioblastoma
January 29th 2016Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A).
Watch
Potential Key Target for Deadly Brain Cancer Identified
January 18th 2016Building on previous work showing increased NF-kB activity in lung cancers, one research team has recently published a study showing this activity is also enhanced in glioblastoma, one of the most lethal forms of human cancers.
Read More
Dr. Rimas Lukas on the Future of Checkpoint Inhibitors in Recurrent Glioblastoma
November 20th 2015Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, on PD-L1 blockade treatment and its potential in patients with recurrent glioblastoma (GBM).
Watch
Scientists Uncover Potential TMZ-Resistance Reversal in Glioblastoma
November 20th 2015A team of scientists from Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic may have found a way to increase sensitivity to the front-line chemotherapeutic agent temozolomide (TMZ) in glioblastoma (GBM), even after resistance.
Read More
DNA Immunotherapy Candidate for Head & Neck Cancer Part of New Pharma Collaboration
August 14th 2015AstraZeneca’s MedImmune has entered into a licensing agreement and collaboration with Inovio Pharmaceuticals, whereby MedImmune was given exclusive rights to Inovio’s INO-3112 immunotherapy.
Read More
Historic OS Benefit Seen in Phase II Glioblastoma Study
June 25th 2015David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, and president, Society for Neuro-Oncology, discusses rindopepimut (CDX-110), a synthetic peptide vaccine, and its potential in brain cancer based on the results of the ReACT Trial.
Read More
Low-Dose Bevacizumab With Chemo Not Helpful in Recurrent Glioblastoma
June 8th 2015Low-dose bevacizumab combined with lomustine has no significant effect on progression-free survival (PFS) or overall survival (OS) compared with standard-dose bevacizumab alone in patients with recurrent glioblastoma, according to results from a randomized phase II study.
Read More
Glioma Therapy Trial Reveals Key Role of Molecular Signature for Outcome
June 7th 2015A reanalysis of a phase III clinical trial in glioma patients confirms that there is no difference for a radiotherapy-first versus a chemotherapy-first strategy, but there is a major difference in long-term outcomes for molecular stratification independent of treatment.
Read More
Reardon on ReACT: First Immunotherapy to Show Benefit in Glioblastoma
June 5th 2015Targeted Oncology spoke with David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president of the Society for Neuro-Oncology, and lead author on the ReACT trial to better understand the significance of the study results for patients with glioblastoma.
Read More
Genomic Profiling Provides Much-Needed Prognostic Data in Glioma
June 4th 2015Results from a genomic and molecular analysis presented at the 2015 ASCO Annual Meeting and published in Acta Neuropathology indicate that low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.
Read More